SCHEMBL14935449

SCHEMBL14935449

CCC1(CCc2ccccc2)NC(=O)NC1=O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.46
HSD11B1 P28845 1/20 0.44
MMP13 P45452 3/20 0.44
MMP2 P08253 3/20 0.44
MMP9 P14780 3/20 0.44
MMP8 P22894 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
FPR2 P25090 1/20 0.43
PDE7A Q13946 1/20 0.42
ADAMTS5 Q9UNA0 1/20 0.41
CACNA1F O60840 1/20 0.41
MAPT P10636 1/20 0.41
CYP2C9 P11712 1/20 0.41
HTR2A P28223 1/20 0.41
HRH1 P35367 1/20 0.41
SCN1A P35498 1/20 0.41
SCN4A P35499 1/20 0.41
BLM P54132 1/20 0.41
PMP22 Q01453 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14935456 0.83 MMP9 (0.45) ALDH1A1MMP13MMP2MMP9MMP8
SCHEMBL5935684 0.78 ALDH1A1 (0.42) ALDH1A1HSD11B1MMP13MMP2MMP9
SCHEMBL13103908 0.78 ALDH1A1 (0.42) ALDH1A1HSD11B1MMP13MMP2MMP9
SCHEMBL9584263 0.78 SMN1; SMN2 (0.68) ALDH1A1MMP13MMP2MMP9MMP8
SCHEMBL4174555 0.77 CYP3A4 (0.49) ALDH1A1MMP13MMP2MMP9MMP8
SCHEMBL27952144 0.76 MMP9 (0.58) ALDH1A1MMP13MMP2MMP9MMP8
SCHEMBL6699900 0.76 PDE7A (0.44) ALDH1A1SMN1; SMN2NPSR1PDE7AADAMTS5
SCHEMBL1404437 0.75 LMNA (0.50) ALDH1A1SMN1; SMN2NPSR1PDE7AADAMTS5
SCHEMBL14945778 0.74 FPR2 (0.52) ALDH1A1HSD11B1NPSR1FPR2ATM
SCHEMBL6692266 0.73 LMNA (0.40) ALDH1A1MMP13MMP2MMP9MMP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3103797-B1 2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS ALLERGAN INC (US) 2019-04-10 EP disclosed
EP-3103797-A1 2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS ALLERGAN, INC. (US) 2016-12-14 EP disclosed
EP-2776403-B1 2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS ALLERGAN INC (US) 2016-09-14 EP disclosed
US-20130123215-A1 2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS ALLERGAN, INC. (US) 2013-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123215-A1 2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS FPR1, FPR2, FPR3 ALDH1A1 3811/4885HSD11B1 4486/4885MMP13 3938/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.